Physician profile
Xavier Caro
NPI 1477656353
$1,567.52
in general payments reported to CMS, 2019-2025
7 companies · $862 in 2025
The $862 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.70 · 2020: $14.18 · 2021: $144 · 2022: $57.16 · 2023: $203 · 2024: $218 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282 · Education: $0.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.23 |
| Education | $0.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $918.68 | 2022-2025 | Krystexxa, Otezla, Tavneos |
| Astrazeneca Pharmaceuticals LP | $269.60 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $123.06 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $122.07 | 2025 | Benlysta |
| Pfizer INC. | $80.07 | 2019-2021 | |
| Invivyd INC | $32.81 | 2025 | Pemgarda |
| Janssen Biotech, INC. | $21.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xavier Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.